NRAS Q61K — same therapeutic rationale as Q61R. ICI 1L; binimetinib NEMO subgroup.
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NRAS-Q61K-MELANOMA |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CIVIC SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | NRAS Q61K |
| Disease | DIS-MELANOMA |
| ESCAT tier | IB |
| Recommended combinations | anti-PD1-based ICI, binimetinib (off-label) |
| Evidence summary | NRAS Q61K — same therapeutic rationale as Q61R. ICI 1L; binimetinib NEMO subgroup. |
Notes
ESCAT IB. Under BIO-RAS-MUTATION (no dedicated BIO-NRAS-Q61K yet — flag for BIO authoring).
Used By
No reverse references found in the YAML corpus.